help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hintz, R. L.
Right arrow Articles by Liu, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hintz, R. L.
Right arrow Articles by Liu, F.

Journal of Clinical Endocrinology & Metabolism, Vol 45, 988-995, Copyright © 1977 by Endocrine Society

ARTICLES

Demonstration of specific plasma protein binding sites for somatomedin

RL Hintz and F Liu

Native somatomedin (SM) has an apparent mol wt of at least 60,000 daltons, while all the purified SM peptides have mol wt 5-8,000 daltsons. We have studied the behavior of somatomedin in plasma during gel filtration at pH 8.1 and pH 2.8, and by the recombination of fractions. Using porcine bioassay for SM, displacement of 125I-insulin by SM, and binding of 125I-SM to plasma proteins, we can demonstrate that the disparity in apparent mol wt of SM is due to reversible binding to plasma proteins which are themselves biologically inactive. This binding site is specific for the SM peptides, saturable, and has high affinity and relatively low capacity.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. Nakae, M. Kato, M. Murashita, N. Shinohara, T. Tajima, and K. Fujieda
Long-Term Effect of Recombinant Human Insulin-Like Growth Factor I on Metabolic and Growth Control in a Patient with Leprechaunism
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 542 - 549.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
R. G. Rosenfeld and Y. Oh
Editorial: The Blind Men and the Elephant--A Parable for the Study of Insulin-Like Growth Factor Binding Proteins
Endocrinology, January 1, 1998; 139(1): 5 - 7.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. Rajaram, D. J. Baylink, and S. Mohan
Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions
Endocr. Rev., December 1, 1997; 18(6): 801 - 831.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
S. Manes, L. Kremer, J. P. Albar, C. Mark, R. Llopis, and C. Martinez-A
Functional Epitope Mapping of Insulin-Like Growth Factor I (IGF-I) by Anti-IGF-I Monoclonal Antibodies
Endocrinology, March 1, 1997; 138(3): 905 - 915.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. T. Overgaard, H. B. Boldt, L. S. Laursen, L. Sottrup-Jensen, C. A. Conover, and C. Oxvig
Pregnancy-associated Plasma Protein-A2 (PAPP-A2), a Novel Insulin-like Growth Factor-binding Protein-5 Proteinase
J. Biol. Chem., June 8, 2001; 276(24): 21849 - 21853.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1977 by The Endocrine Society